Marqués-Gallego Patricia, den Dulk Hans, Brouwer Jaap, Kooijman Huub, Spek Anthony L, Roubeau Olivier, Teat Simon J, Reedijk Jan
Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden UniVersity, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Inorg Chem. 2008 Dec 1;47(23):11171-9. doi: 10.1021/ic8014767.
Two new cytotoxic fluorescent platinum(II) compounds, cis-[Pt(A9opy)Cl2] (1) and cis-[Pt(A9pyp)(DMSO)Cl2] (2),have been designed, synthesized, and characterized by IR, 1H NMR, and 195Pt NMR spectroscopy; electrospray ionization mass spectrometry (ESI-MS); and single-crystal X-ray diffraction. The carrier ligands selected for thesynthesis of these fluorescent platinum(II) compounds are E-2-[1-(9-anthryl)-3-oxo-3-prop-2-enylpyridine] (abbreviatedas A9opy) and E-1-(9-anthryl)-3-(2-pyridyl)-2-propenone (abbreviated as A9pyp). The compound cis-Pt(A9opy)Cl2 comprises a peculiar cis-platinum(II) organometallic compound, in which the platinum(II) ion is bound to the photoisomerizable carbon-carbon double bond of the carrier ligand. The effects of the metal-ion coordination on the photoisomerization of the carbon-carbon double bond of the ligand have been studied. In contrast, the carrier ligand A9pyp used for the synthesis of the cis-[Pt(A9pyp)(DMSO)Cl2] compound (2) does not undergo such anisomerization process and remains in the E conformation, while coordinated to the platinum(II) ion through the nitrogen of the pyridine ring. In addition to the synthesis and characterization, solution studies of both compounds have also been performed in detail, including NMR and ESI-MS spectroscopy. Moreover, a high degree of cytotoxicactivity of compound 1 was found, as compared to cisplatin and its corresponding platinum-free molecule, in a series of human tumor cell lines. Compound 2 was also found to be highly active against these cell lines but appeared less active compared to the platinum-free molecule.
设计、合成了两种新型细胞毒性荧光铂(II)化合物,顺式-[Pt(A9opy)Cl₂](1)和顺式-[Pt(A9pyp)(DMSO)Cl₂](2),并通过红外光谱、¹H NMR和¹⁹⁵Pt NMR光谱、电喷雾电离质谱(ESI-MS)以及单晶X射线衍射对其进行了表征。用于合成这些荧光铂(II)化合物的载体配体是E-2-[1-(9-蒽基)-3-氧代-3-丙烯基吡啶](缩写为A9opy)和E-1-(9-蒽基)-3-(2-吡啶基)-2-丙烯酮(缩写为A9pyp)。化合物顺式-[Pt(A9opy)Cl₂](1)是一种特殊的顺铂(II)有机金属化合物,其中铂(II)离子与载体配体的可光异构化碳-碳双键相连。研究了金属离子配位对配体碳-碳双键光异构化的影响。相比之下,用于合成顺式-[Pt(A9pyp)(DMSO)Cl₂]化合物(2)的载体配体A9pyp在通过吡啶环的氮与铂(II)离子配位时,不会发生这种异构化过程,而是保持E构型。除了合成和表征外,还对这两种化合物进行了详细的溶液研究,包括NMR和ESI-MS光谱。此外,在一系列人类肿瘤细胞系中发现,与顺铂及其相应的无铂分子相比,化合物1具有高度的细胞毒性活性。化合物2对这些细胞系也具有高活性,但与无铂分子相比活性似乎较低。